S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
NASDAQ:ORGS

Orgenesis Stock Forecast, Price & News

$3.32
+0.17 (+5.40%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.07
$3.41
50-Day Range
$2.89
$5.08
52-Week Range
$2.88
$8.30
Volume
49,653 shs
Average Volume
208,323 shs
Market Capitalization
$80.59 million
P/E Ratio
155.50
Dividend Yield
N/A
Beta
0.96
30 days | 90 days | 365 days | Advanced Chart
Receive ORGS News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.


Orgenesis logo

About Orgenesis

Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment through MaSTherCell, comprises of services from cell therapy development through cell therapy manufacturing for and companies that provide end-to-end solution. The POC segment provides multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.

Headlines

Orgenesis Inc. (NASDAQ:ORGS) Sees Large Decline in Short Interest
November 21, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ORGS
Fax
N/A
Employees
111
Year Founded
N/A

Sales & Book Value

Annual Sales
$7.65 million
Book Value
$1.78 per share

Profitability

Net Income
$1.11 million
Net Margins
-112.03%
Pretax Margin
-221.07%

Debt

Price-To-Earnings

Miscellaneous

Free Float
22,396,000
Market Cap
$80.59 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/07/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1377th out of 1,394 stocks

Pharmaceutical Preparations Industry

668th out of 673 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Orgenesis (NASDAQ:ORGS) Frequently Asked Questions

How has Orgenesis' stock been impacted by Coronavirus (COVID-19)?

Orgenesis' stock was trading at $3.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ORGS stock has decreased by 14.0% and is now trading at $3.32.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Orgenesis?

Orgenesis saw a decrease in short interest in the month of October. As of October 29th, there was short interest totaling 254,400 shares, a decrease of 17.3% from the October 14th total of 307,500 shares. Based on an average daily volume of 54,700 shares, the short-interest ratio is currently 4.7 days. Approximately 1.2% of the shares of the company are short sold.
View Orgenesis' Short Interest
.

When is Orgenesis' next earnings date?

Orgenesis is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Orgenesis
.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) released its quarterly earnings results on Thursday, November, 4th. The company reported ($0.42) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.39. The firm earned $7.61 million during the quarter. Orgenesis had a negative trailing twelve-month return on equity of 76.79% and a negative net margin of 112.03%.
View Orgenesis' earnings history
.

Who are Orgenesis' key executives?

Orgenesis' management team includes the following people:
  • Vered Caplan, Chairman, President & Chief Executive Officer
  • Neil Reithinger, Chief Financial Officer, Secretary & Treasurer
  • Sarah Ferber, Chief Scientific Officer
  • Heiko von der Leyen, Medical Director

What is Orgenesis' stock symbol?

Orgenesis trades on the NASDAQ under the ticker symbol "ORGS."

Who are Orgenesis' major shareholders?

Orgenesis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.81%), Renaissance Technologies LLC (0.32%), Citadel Advisors LLC (0.00%), Dimensional Fund Advisors LP (0.10%), Millennium Management LLC (0.10%) and Squarepoint Ops LLC (0.10%).
View institutional ownership trends for Orgenesis
.

Which institutional investors are selling Orgenesis stock?

ORGS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Marshall Wace LLP, and Squarepoint Ops LLC.
View insider buying and selling activity for Orgenesis
or view top insider-selling stocks.

Which institutional investors are buying Orgenesis stock?

ORGS stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Geode Capital Management LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Orgenesis
or or view top insider-buying stocks.

How do I buy shares of Orgenesis?

Shares of ORGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orgenesis' stock price today?

One share of ORGS stock can currently be purchased for approximately $3.32.

How much money does Orgenesis make?

Orgenesis has a market capitalization of $80.59 million and generates $7.65 million in revenue each year.

How many employees does Orgenesis have?

Orgenesis employs 111 workers across the globe.

What is Orgenesis' official website?

The official website for Orgenesis is www.orgenesis.com.

Where are Orgenesis' headquarters?

Orgenesis is headquartered at 20271 Goldenrod Lane, Germantown MD, 20876.

How can I contact Orgenesis?

Orgenesis' mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at (480) 659-6404 or via email at [email protected].


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.